GlassScriptPhysician profile
Stephanie Knight
NPI 1750630364
$2,453.09
in general payments reported to CMS, 2019-2025
36 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.04 · 2023: $1,555 · 2024: $649 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.56 |
| Education | $167.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $623.57 | 2023-2025 | Octrode, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $204.87 | 2023-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $163.82 | 2023 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $152.39 | 2023-2024 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $150.96 | 2023 | Ninlaro |
| Incyte Corporation | $98.08 | 2023-2024 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $94.60 | 2023 | |
| Progenics Pharmaceuticals, INC. | $86.67 | 2023 | Pylarify |
| Daiichi Sankyo INC. | $68.90 | 2023-2024 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $56.74 | 2023-2024 | Erleada, Darzalex, Tecvayli |
| Glaxosmithkline, LLC. | $54.32 | 2023-2024 | Ojjaara |
| Abbvie INC. | $54.00 | 2021-2024 | |
| Genmab U.S., INC. | $49.94 | 2023-2024 | Epkinly, Tivdak |
| Karyopharm Therapeutics INC. | $49.31 | 2023 | Xpovio |
| Genentech USA, INC. | $48.04 | 2023 | Venclexta, Polivy, Tecentriq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.32 | 2023 | |
| Xeris Pharmaceuticals, INC. | $37.31 | 2024 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $35.06 | 2023-2024 | Sylvant |
| Pfizer INC. | $34.95 | 2023-2024 | |
| Genzyme Corporation | $30.01 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $25.05 | 2023 | Tazverik |
| Adaptive Biotechnologies Corporation | $24.53 | 2024 | Clonoseq |
| Stemline Therapeutics INC. | $22.88 | 2023 | Orserdu |
| Pharmaessentia USA Corporation | $22.76 | 2023 | Besremi |
| Alexion Pharmaceuticals, INC. | $22.74 | 2023 | Ultomiris |
| Amgen INC. | $21.96 | 2023 | Kyprolis, Blincyto |
| Insulet Corporation | $21.49 | 2024 | Omnipod |
| Janssen Scientific Affairs, LLC | $20.44 | 2023 | Darzalex, Tecvayli |
| Mylan Institutional INC. | $18.63 | 2023 | Fulphila, Ogivri |
| Corcept Therapeutics | $18.47 | 2024 | Korlym |
| Blueprint Medicines Corporation | $17.69 | 2024 | Ayvakit |
| Gilead Sciences, INC. | $16.71 | 2024 | |
| Rigel Pharmaceuticals, INC. | $16.53 | 2023 | Tavalisse, Rezlidhia |
| Medtronic, INC. | $16.37 | 2023 | Minimed 780g |
| Eisai INC. | $16.02 | 2023 | |
| Taiho Oncology, INC. | $15.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.